This site is intended for Healthcare professionals only.

Buprenorphine-naloxone preferred first-line treatment for opioid use disorder -Canadian guidelines


Buprenorphine-naloxone preferred first-line treatment for opioid use disorder -Canadian guidelines

A new Canadian guideline for managing opioid use disorders has been released.This has been created for a wide range of healthcare providers to address an urgent need for evidence-based treatment of opioid use causing overdoses and death.It lays out the optimal strategies for the treatment of opioid addiction, including recommending opioid agonist treatment with buprenorphine-naloxone as the preferred first-line treatment. The guideline have been published in CMAJ (Canadian Medical Association Journal).

In 2016, the rate of opioid-related deaths in Canada was 7.9 per 100 000 (a total of 2861 deaths), and the number of deaths continues to increase. The opioid epidemic affecting both Canada and the United States is fuelled by a combination of overprescribing as well as the influx of highly potent illegal synthetic opioids, such as illicitly manufactured fentanyl.

“Opioid use disorder is a public health emergency nationwide and this guideline provides a blueprint for health practitioners to step up and provide evidence-based care,” says Dr. Julie Bruneau lead author of the pan-Canadian guideline group and a physician at the Centre Hospitalier de l’Université de Montréal.

“Traditionally, resources for the treatment of opioid addiction have been scarce, and guidelines outlining best practices and practices to avoid have been lacking,” says Dr. Evan Wood, senior author and director of the BC Centre on Substance Use at St. Paul’s Hospital and the University of British Columbia.

To address the traditional gaps in knowledge in this area, the guideline aims to provide Canadian health care professionals and health authorities with national clinical practice recommendations for treating opioid use disorder. The review panel included 43 health care practitioners with broad experience who are part of the Canadian Institutes of Health Research’s Canadian Research Initiative in Substance Misuse (CRISM). The guideline group also involved people with opioid use disorder experience and considered patient values and preferences in developing its recommendations.

Key recommendations:

  • Start opioid agonist treatment with buprenorphine-naloxone whenever possible to reduce risk of toxicity, illness and death
  • In people who respond poorly to buprenorphine-naloxone, consider transitioning to methadone treatment
  • Start opioid agonist treatment with methadone when buprenorphine-naloxone is not the preferred option
  • In people who respond well to methadone and who want simpler treatment, consider transitioning to buprenorphine-naloxone
  • In patients who do not respond to the above therapies, consider slow-release oral morphine, prescribed as daily witnessed doses
  • Avoid withdrawal management alone without transition to long-term treatment to reduce risk of relapse and death.

Opioid agonist treatment with buprenorphine-naloxone is recommended as first-line treatment because of its better safety record, including lower risk of overdose and lower risk of breathing suppression; ease of use, especially in rural and remote areas where daily witnessed ingestion is not practical; dosing flexibility; and milder withdrawal symptoms if stopping treatment, making it a better option for people with milder opioid dependence.

Beyond recommending best practices, like the use of buprenorphine-naloxone as first-line treatment whenever possible, the guideline also identifies how certain common practices in the Canadian health care system should be avoided — specifically, how offering withdrawal management as an isolated strategy for the treatment of opioid use disorder actually increases rates of overdose.

“With these recommendations laid out, there is an urgent need for health systems to look at the historical gaps in care and invest in providing timely and evidence-based treatment, says Dr. Bruneau, who is also a professor in the Faculty of Medicine at Université de Montréal. “By encouraging physicians to work alongside their patients to identify the safest, most effective approach first, these new guidelines ensure the best science and evidence are integrated into care.”

Opioid use disorder is often a chronic, relapsing condition associated with increased morbidity and risk of death. However, with appropriate treatment and follow-up, individuals can reach sustained long-term remission.

For more details click on the link: http://www.cmaj.ca/lookup/doi/10.1503/cmaj.180209

The following two tabs change content below.
Anjali Nimesh

Anjali Nimesh

Anjali Nimesh Joined Medical Dialogue as Reporter in 2016. she covers all the medical specialty news in different medical categories. She also covers the Medical guidelines, Medical Journals, rare medical surgeries as well as all the updates in medical filed. She is a graduate from Dr. Bhimrao Ambedkar University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Source: Eureka Alert

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted